Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: Systematic review

Current Medical Research and Opinion

Volumn 27, Issue 8, 2011, Pages 1571-1583

  Hallett, Lindsay ^a   Foster, Talia ^a   Liu, Zhimei ^b   Blieden, Marissa ^a   Valentim, Joice ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Cardiovascular and Metabolism Unit   (Brazil)

Author keywords

Clinical; Economic; Humanistic; Tuberous sclerosis

Indexed keywords

ETIRACETAM; EVEROLIMUS; LAMOTRIGINE; PLACEBO; RAPAMYCIN; VIGABATRIN;

AGGRESSION; ANGIOMYOLIPOMA; ANXIETY DISORDER; ASTROCYTOMA; ATTENTION DEFICIT DISORDER; AUTISM; CYST; DEPIGMENTATION; DEPRESSION; DRUG SAFETY; EPILEPSY; HAMARTOMA; HEMANGIOFIBROMA; HUMAN; HYPERMETROPIA; INFANTILE SPASM; IRELAND; IRIS COLOBOMA; KETOGENIC DIET; KIDNEY CARCINOMA; KIDNEY POLYCYSTIC DISEASE; LEARNING DISORDER; LIPID DIET; LOW CARBOHYDRATE DIET; MENTAL DEFICIENCY; MYOPIA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; RETINAL TOXICITY; REVIEW; RHABDOMYOMA; SKIN DEFECT; SLEEP DISORDER; STRABISMUS; SYSTEMATIC REVIEW; TAIWAN; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 79960419102     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.586687     Document Type: Review

References (157)

1. National Institute of Neurological Disorders and Stroke. Tuberous Sclerosis Fact Sheet. Available at: http://www.ninds.nih.gov/disorders/tuberous- sclerosis/detail-tuberous-sclerosis.htm#107073220 [Last accessed 13 May 2010].
2. Tuberous Sclerosis Association, UK. Tuberous Sclerosis Association, UK. Clinical guidelines for the care of patients with Tuberous Sclerosis Complex: Summary. Available at: http://www.tuberous-sclerosis.org/publications/ clinicalguidelinessummary.pdf [Last accessed 12 May 2010].
3. Au KS, Williams AT, Gambello MJ, et al. Molecular genetic basis of tuberous sclerosis complex: from bench to bedside. J Child Neurol 2004;19:699-709. (Pubitemid 39530080)
4. Baskin Jr HJ. The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol 2008;38:936-52.
5. Camposano SE, Greenberg E, Kwiatkowski DJ, et al. Distinct clinical characteristics of tuberous sclerosis complex patients with no mutation identified. Ann Hum Genet 2009;73:141-6.
6. Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80. (Pubitemid 32048362)
7. Hottinger AF, Khakoo Y. Update on the management of familial central nervous system tumor syndromes. Curr Neurol Neurosci Rep 2007;7:200-7. (Pubitemid 46831513)
8. Stables G, Sheehan-Dare R. The dermatological features of tuberous sclerosis and their treatment. (2000) Fact-Sheet No. 25 of the Tuberous Sclerosis Association. 2000. Available at: http://www.tuberous-sclerosis. org/publications/fs25derm.pdf [Last accessed 12 May 2010].
9. Yates JR. Tuberous sclerosis. Eur J Hum Genet 2006;14:1065-73. (Pubitemid 44463964)
10. Crino PB. The pathophysiology of tuberous sclerosis complex. Epilepsia 2010;51(Suppl 1):27-9.
11. Farrell CJ, Plotkin SR. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin 2007;25:925-46,viii. (Pubitemid 47610810)
12. Inoki K, Guan KL. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet 2009;18(R1):R94-100.
13. Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004;63:1236-42. (Pubitemid 39603395)
14. Ess KC. The neurobiology of tuberous sclerosis complex. Semin Pediatr Neurol 2006;13:37-42. (Pubitemid 43963399)
15. Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs 2008;10:299-313.
16. Sampson JR. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans 2009;37(Pt 1):259-64.
17. Isaacs H. Perinatal (fetal and neonatal) tuberous sclerosis: a review. Am J Perinatol 2009;26:755-60.
18. Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc Nephrol 2009;4:1998-2007.
19. Castagnetti M, Vezzu B, Laverda A, et al. Urological counseling and followup in pediatric tuberous sclerosis complex. J Urol 2007;178:2155-9. (Pubitemid 47538629)
20. de Vries PJ, Hunt A, Bolton PF. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry 2007;16:16-24. (Pubitemid 46648361)
21. Henske EP, Ewalt DH, Bissler JJ. Tuberous Sclerosis Alliance. Renal manifestations in tuberous sclerosis complex. June 2006. Available at: http://www.tsalliance.org/documents/Renal%20Manifestations%20in%20TSC.pdf [Last accessed 13 May 2010].
22. O'Callaghan FJ, Noakes MJ, Martyn CN, et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 2004;94:853-7. (Pubitemid 39472484)
23. Rakowski SK, Winterkorn EB, Paul E, et al. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int 2006;70:1777-82. (Pubitemid 44684809)
24. Jozwiak J, Jozwiak S, Oldak M. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev 2006;26:160-80. (Pubitemid 43334640)
25. Akinci A, Oner O, Guven A, et al. Refractive errors and strabismus in children with tuberous sclerosis: a controlled study. J Pediatr Ophthalmol Strabismus 2009;46:345-8.
26. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000;75:591-4. (Pubitemid 30395921)
27. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-56.
28. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657-68.
29. Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respir Med 2002;96:1-6. (Pubitemid 41122762)
30. Curatolo P, D'Argenzio L, Cerminara C, et al. Management of epilepsy in tuberous sclerosis complex. Expert Rev Neurother 2008;8:457-67. (Pubitemid 351480908)
31. Gomez MR, Sampson JR, Whittemore VH. Tuberous Sclerosis Complex, 3rd edn. New York and Oxford: Oxford University Press, 1999.
32. Leung AK, Robson WL. Tuberous sclerosis complex: a review. J Pediatr Health Care 2007;21:108-14.
33. Kalantari BN, Salamon N. Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging. AJR Am J Roentgenol 2008; 190:W304-9. (Pubitemid 351684938)
34. Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004;63:1457-61. (Pubitemid 39426281)
35. Shepherd CW, Beard CM, Gomez MR, et al. Tuberous sclerosis complex in Olmsted County, Minnesota, 1950-1989. Arch Neurol 1991;48:400-1.
36. Tuberous Sclerosis Association, UK. Subependymal giant cell tumours in tuberous sclerosis complex. 2006. Available at: http://www.tuberous-sclerosis. org/publications/fs26sgct.pdf [Last accessed 12 May 2010].
37. de Vries P, Humphrey A, McCartney D, et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry 2005;14:183-90.
38. de Vries PJ, Gardiner J, Bolton PF. Neuropsychological attention deficits in tuberous sclerosis complex (TSC). Am J Med Genet A 2009;149A:387-95.
39. Moss J, Howlin P. Autism spectrum disorders in genetic syndromes: implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. J Intellect Disabil Res 2009;53:852-73.
40. Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord 1998; 28:407-14. (Pubitemid 29101856)
41. Tuberous Sclerosis Alliance. TSC and autism spectrum disorders. June 2006. Available at: http://www.tsalliance.org/documents/TSC%20and%20 Autism%20Spectrum%20Disorders.pdf [Last accessed 12 May 2010].
42. Zafeiriou DI, Ververi A, Vargiami E. Childhood autism and associated comorbidities. Brain Dev 2007;29:257-72. (Pubitemid 46483916)
43. Au KS, Williams AT, Roach ES, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 2007;9:88-100.
44. Mitchell AL, Parisi MA, Sybert VP. Effects of pregnancy on the renal and pulmonary manifestations in women with tuberous sclerosis complex. Genet Med 2003;5:154-60. (Pubitemid 36998677)
45. Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol 2002;168(4 Pt 1):1315-25. (Pubitemid 35034114)
46. Bader RS, Chitayat D, Kelly E, et al. Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr 2003;143:620-4. (Pubitemid 37452789)
47. Di Liang C, Ko SF, Huang SC. Echocardiographic evaluation of cardiac rhabdomyoma in infants and children. J Clin Ultrasound 2000;28:381-6.
48. Chao AS, Chao A, Wang TH, et al. Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and a meta-analysis. Ultrasound Obstet Gynecol 2008;31:289-95.
49. Hancock E, Tomkins S, Sampson J, et al. Lymphangioleiomyomatosis and tuberous sclerosis. Respir Med 2002;96:7-13. (Pubitemid 41122763)
50. Rowley SA, O'Callaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol 2001;85:420-3. (Pubitemid 32275621)
51. Hohman DW, Noghrehkar D, Ratnayake S. Lymphangioleiomyomatosis: a review. Eur J Intern Med 2008;19:319-24.
52. Moss J, Avila NA, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001;164:669-71. (Pubitemid 32801675)
53. Muzykewicz DA, Newberry P, Danforth N, et al. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav 2007;11:506-13. (Pubitemid 350177384)
54. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001;164:661-8. (Pubitemid 32801674)
55. Devlin LA, Shepherd CH, Crawford H, et al. Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland. Dev Med Child Neurol 2006;48:495-9. (Pubitemid 43740913)
56. Hong CH, Darling TN, Lee CH. Prevalence of tuberous sclerosis complex in Taiwan: a national population-based study. Neuroepidemiology 2009; 33:335-41.
57. Anlauf M, Garbrecht N, Bauersfeld J, et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch 2007;451(Suppl 1): S29-38. (Pubitemid 47283381)
58. Holmes GL, Stafstrom CE. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 2007;48:617-30. (Pubitemid 46587608)
59. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 1991;615:125-7.
60. O'Callaghan FJ. Tuberous sclerosis. BMJ 1999;318:1019-20. (Pubitemid 29191885)
61. Wong V. Study of the relationship between tuberous sclerosis complex and autistic disorder. J Child Neurol 2006;21:199-204. (Pubitemid 43891144)
62. Ohtsuka Y, Yoshinaga H, Kobayashi K. Refractory childhood epilepsy and factors related to refractoriness. Epilepsia 2000;41(Suppl 9):14-17. (Pubitemid 32002746)
63. Raznahan A, Higgins NP, Griffiths PD, et al. Biological markers of intellectual disability in tuberous sclerosis. Psychol Med 2007;37:1293-304. (Pubitemid 47244859)
64. Raznahan A, Joinson C, O'Callaghan F, et al. Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis. J Intellect Disabil Res 2006; 50(Pt 8):561-9. (Pubitemid 44027277)
65. Chu-Shore C, Major P, Montenegro M, et al. Cystic Cortical Tubers are predictive of the development of epilepsy in patients with tuberous sclerosis complex. Epilepsia 2008; (Suppl 0):Abstract 1.174.
66. Hunt A. Development, behaviour and seizures in 300 cases of tuberous sclerosis. J Intellect Disabil Res 1993;37(Pt 1):41-51. (Pubitemid 23099951)
67. Gallagher A, Chu-Shore CJ, Montenegro MA, et al. Associations between electroencephalographic and magnetic resonance imaging findings in tuberous sclerosis complex. Epilepsy Res 2009;87:197-202.
68. Liou HH, Oon PC, Lin HC, et al. Risk factors associated with infantile spasms: a hospital-based case-control study in Taiwan. Epilepsy Res 2001;47:91-8.
69. Primec ZR, Kopac S, Neubauer D. Epidemiologic features of infantile spasms in Slovenia. Epilepsia 2002;43:183-7. (Pubitemid 34226000)
70. Riikonen R. Epidemiological data of West syndrome in Finland. Brain Dev 2001;23:539-41. (Pubitemid 32999122)
71. Adriaensen ME, Schaefer-Prokop CM, Stijnen T, et al. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 2009;16:691-6.
72. O'Callaghan FJ, Martyn CN, Renowden S, et al. Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study. Arch Dis Child 2008;93:751-4.
73. Joinson C, O'Callaghan FJ, Osborne JP, et al. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 2003;33:335-44. (Pubitemid 36221465)
74. D'Agati E, Moavero R, Cerminara C, et al. Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex. J Child Neurol 2009; 24:1282-7.
75. Goh S, Kwiatkowski DJ, Dorer DJ, et al. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology 2005; 65:235-8. (Pubitemid 41022367)
76. Winterkorn EB, Pulsifer MB, Thiele EA. Cognitive prognosis of patients with tuberous sclerosis complex. Neurology 2007;68:62-4. (Pubitemid 46058555)
77. O'Callaghan FJ, Harris T, Joinson C, et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 2004; 89:530-3.
78. Bolton PF, Park RJ, Higgins JN, et al. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 2002;125(Pt 6): 1247-55. (Pubitemid 34587134)
79. Jeste SS, Sahin M, Bolton P, et al. Characterization of autism in young children with tuberous sclerosis complex. J Child Neurol 2008;23:520-5. (Pubitemid 351566864)
80. Humphrey A, Williams J, Pinto E, et al. A prospective longitudinal study of early cognitive development in tuberous sclerosis-a clinic based study. Eur Child Adolesc Psychiatry 2004;13:159-65. (Pubitemid 38915705)
81. Australasian Tuberous Sclerosis Society. Clinical guidelines for the care of patients with tuberous sclerosis complex. November 2009. Available at: http://www.atss.org.au/images/stories/clinical%20guidelines%202009.pdf [Last accessed 13 May 2010].
82. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(Suppl 1):S1-56;quiz S9-60.
83. Wheless JW, Clarke DF, Arzimanoglou A, et al. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9:353-412. (Pubitemid 351147653)
84. Hyman MH, Whittemore VH. National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 2000;57:662-5. (Pubitemid 30252800)
85. Anisya-Vasanth AV, Satishchandra P, Nagaraja D, et al. Spectrum of epilepsy in tuberous sclerosis. Neurol India 2004;52:210-12. (Pubitemid 39136954)
86. Sooriakumaran P, Gibbs P, Coughlin G, et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int 2009;105(1):101-6.
87. Humphrey A, Ploubidis GB, Yates JR, et al. The Early Childhood Epilepsy Severity Scale (E-Chess). Epilepsy Res 2008;79:139-45.
88. Bollo RJ, Kalhorn SP, Carlson C, et al. Epilepsy surgery and tuberous sclerosis complex: special considerations. Neurosurg Focus 2008;25:E13.
89. Connolly MB, Hendson G, Steinbok P. Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects. Childs Nerv Syst 2006;22:896-908. (Pubitemid 44103018)
90. Hottinger AF, Khakoo Y. Neurooncology of familial cancer syndromes. J Child Neurol 2009;24:1526-35.
91. Jansen FE, van Huffelen AC, Algra A, et al. Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia 2007;48:1477-84. (Pubitemid 47245804)
92. Jarrar RG, Buchhalter JR, Raffel C. Long-term outcome of epilepsy surgery in patients with tuberous sclerosis. Neurology 2004;62:479-81. (Pubitemid 38200866)
93. Koh S, Jayakar P, Dunoyer C, et al. Epilepsy surgery in children with tuberous sclerosis complex: presurgical evaluation and outcome. Epilepsia 2000;41:1206-13.
94. Landry CS, Waguespack SG, Perrier ND. Surgical management of nonmultiple endocrine neoplasia endocrinopathies: state-of-the-art review. Surg Clin North Am 2009;89:1069-89.
95. Luat AF, Makki M, Chugani HT. Neuroimaging in tuberous sclerosis complex. Curr Opin Neurol 2007;20:142-50. (Pubitemid 46411498)
96. Madhavan D, Schaffer S, Yankovsky A, et al. Surgical outcome in tuberous sclerosis complex: a multicenter survey. Epilepsia 2007;48:1625-8. (Pubitemid 47245802)
97. Mennel S, Meyer CH, Peter S, et al. Current treatment modalities for exudative retinal hamartomas secondary to tuberous sclerosis: review of the literature. Acta Ophthalmol Scand 2007;85:127-32.
98. Papadavid E, Markey A, Bellaney G, et al. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Br J Dermatol 2002;147:337-42.
99. Shenkman Z, Rockoff MA, Eldredge EA, et al. Anaesthetic management of children with tuberous sclerosis. Paediatr Anaesth 2002;12:700-4. (Pubitemid 35478087)
100. Teutonico F, Carlson C, LaJoie J, et al. Epilepsy surgery for children with tuberous sclerosis complex and multi-focal EEG findings. Epilepsia 2008; (Suppl 0):Abstract No. 2.297.
101. Weiner HL, Carlson C, Ridgway EB, et al. Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach. Pediatrics 2006; 117:1494-502. (Pubitemid 46071375)
102. Wu JY, Salamon N, Kirsch HE, et al. Noninvasive testing, early surgery, and seizure freedom in tuberous sclerosis complex. Neurology 2010;74:392-8.
103. Jansen FE, Van Huffelen AC, Van Rijen PC, et al. Epilepsy surgery in tuberous sclerosis: the Dutch experience. Seizure 2007;16:445-53. (Pubitemid 46840291)
104. Teutonico F, Mai R, Devinsky O, et al. Epilepsy surgery in tuberous sclerosis complex: early predictive elements and outcome. Childs Nerv Syst 2008; 24:1437-45.
105. Sharma MC, Ralte AM, Gaekwad S, et al. Subependymal giant cell astrocytoma-a clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res 2004;10:219-24. (Pubitemid 40127699)
106. Cuccia V, Zuccaro G, Sosa F, et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 2003;19:232-43. (Pubitemid 36798785)
107. Romanelli P, Verdecchia M, Rodas R, et al. Epilepsy surgery for tuberous sclerosis. Pediatr Neurol 2004;31:239-47. (Pubitemid 39298448)
108. Curatolo P, Bombardieri R, Cerminara C. Current management for epilepsy in tuberous sclerosis complex. Curr Opin Neurol 2006;19:119-23.
109. Kossoff EH, Thiele EA, Pfeifer HH, et al. Tuberous sclerosis complex and the ketogenic diet. Epilepsia 2005;46:1684-6. (Pubitemid 44921946)
110. Parain D, Penniello MJ, Berquen P, et al. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol 2001;25:213-16. (Pubitemid 32913137)
111. Thiele EA. Managing epilepsy in tuberous sclerosis complex. J Child Neurol 2004;19:680-6. (Pubitemid 39530077)
112. Camposano SE, Major P, Halpern E, et al. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia 2008;49:1186-91. (Pubitemid 351991397)
113. Collins JJ, Tudor C, Leonard JM, et al. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol 2006;21:53-7. (Pubitemid 43778766)
114. Crino PB. Rapamycin and tuberous sclerosis complex: from Easter Island to epilepsy. Ann Neurol 2008;63:415-17. (Pubitemid 351614707)
115. Ess KC. Tuberous sclerosis complex: a brave new world? Curr Opin Neurol 2010;23:189-93.
116. Franz DN, Tudor C, Leonard J, et al. Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia 2001;42:935-40. (Pubitemid 32783104)
117. Hancock E, Osborne JP, Milner P. The treatment of West syndrome: a Cochrane review of the literature to December 2000. Brain Dev 2001; 23:624-34. (Pubitemid 32999138)
118. Jozwiak S, Kotulska K, Domanska-Pakiela D, et al. Treatment of epileptogenic activity on EEG prevents epilepsy and psychomotor delay in children with tuberous sclerosis. Epilepsia 2009; (Suppl 0):Abstract No. 2.091.
119. Mackay M, Weiss S, Snead 3rd OC. Treatment of infantile spasms: an evidence-based approach. Int Rev Neurobiol 2002;49:157-84.
120. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004;62:1668-81. (Pubitemid 38661719)
121. Malphrus AD, Wilfong AA. Use of the newer antiepileptic drugs in pediatric epilepsies. Curr Treat Options Neurol 2007;9:256-67. (Pubitemid 47064609)
122. Martignoni G, Pea M, Reghellin D, et al. PEComas: the past, the present and the future. Virchows Arch 2008;452:119-32.
123. Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007;57:1046-50. (Pubitemid 350087332)
124. Parisi P, Bombardieri R, Curatolo P. Current role of vigabatrin in infantile spasms. Eur J Paediatr Neurol 2007;11:331-6. (Pubitemid 47541933)
125. Riikonen RS. Steroids or vigabatrin in the treatment of infantile spasms? Pediatr Neurol 2000;23:403-8.
126. Siroky BJ, Czyzyk-Krzeska MF, Bissler JJ. Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms? Nat Clin Pract Nephrol 2009;5:143-56.
127. Wheless JW, Ramsay RE, Collins SD. Vigabatrin. Neurotherapeutics 2007; 4:163-72. (Pubitemid 46107327)
128. Willmore LJ, Abelson MB, Ben-Menachem E, et al. Vigabatrin: 2008 update. Epilepsia 2009;50:163-73.
129. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2008(4):CD001770.
130. Curatolo P, Seri S, Verdecchia M, et al. Infantile spasms in tuberous sclerosis complex. Brain Dev 2001;23:502-7. (Pubitemid 32999116)
131. Riikonen R. The latest on infantile spasms. Curr Opin Neurol 2005;18:91-5. (Pubitemid 40477481)
132. Jiang T, Jia G, Ma Z, et al. The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. Childs Nerv Syst 2011;27:55-62.
133. Galanopoulou A, Crino P, Wong M, et al. Rapamycin: From tuberous sclerosis and beyond. Investigator Workshop No. IW.07 at the 2009 Annual Meeting of the American Epilepsy Society. Epilepsia 2009; 50(Suppl s11):309.
134. Franz DN, Krueger DA, Care MM, et al. Everolimus for subependymal giantcell astrocytimas (SEGAs) in tuberous sclerosis (TS). J Clin Oncol 2010;28(7s):Abstract No. 2004.
135. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-8. (Pubitemid 43358069)
136. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801-11.
137. U.S. National Institutes of Health. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/[Last accessed 24 January 2011]. ClinicalTrials.gov is a registry and results database of federally and privately supported clinical trials conducted in the United States and around the world.
138. Searched for trials on Everolimus in TSC. Available at: http://clinicaltrials.gov/ct2/results? termeverolimus\+in\+TSC.
139. Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-deficit/ hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 2008;12:217-33.
140. Jones AC, Sampson JR, Hoogendoorn B, et al. Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis. Hum Genet 2000;106:663-8. (Pubitemid 30427022)
141. Steiger HJ. Preventive neurosurgery: population-wide check-up examinations and correction of asymptomatic pathologies of the nervous system. Acta Neurochir (Wien) 2006;148:1075-83;discussion 83.
142. Valentim J. Long-term disability cost in tuberous sclerosis complex (TSC) in Brazil. Prague, Czech Republic: ISPOR, 2010.
143. Ferguson AP, McKinlay IA, Hunt A. Care of adolescents with severe learning disability from tuberous sclerosis. Dev Med Child Neurol 2002;44:256-62. (Pubitemid 34406515)
144. Kopp CM, Muzykewicz DA, Staley BA, et al. Behavior problems in children with tuberous sclerosis complex and parental stress. Epilepsy Behav 2008;13:505-10.
145. Sabaz M, Lawson JA, Cairns DR, et al. Validation of the quality of life in childhood epilepsy questionnaire in American epilepsy patients. Epilepsy Behav 2003;4:680-91. (Pubitemid 38035691)
146. Schwartz RA, Fernandez G, Kotulska K, et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007;57:189-202. (Pubitemid 47048880)
147. Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2009;51:1236-41.
148. Tuberous Sclerosis Association UK. Effects of TSC. Available at: http://www.tuberous-sclerosis.org/?page-id58 [Last accessed 13 May 2010].
149. Wienecke R, Fackler I, Linsenmaier U, et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006;48:e27-9. (Pubitemid 44262422)
150. Lantin RL. Tuberous Sclerosis Alliance. Heart manifestations in TSC. June. 2006. http://www.tsalliance.org/documents/Heart% 20Manifestations%20in%20TSC.pdf [Last accessed 13 May 2010].
151. Kingwood JC. Monitoring kidney problems in tuberous sclerosis. (2001) Fact-sheet No. 21 of the Tuberous Sclerosis Association. 2001. Available at: http://www.tuberous-sclerosis.org/publications/fs24kidney.pdf [Last accessed 13 May 2010].
152. TSC Canada. Tuberous Sclerosis Information Page. Available at: http://www.tscanada.ca/tscinfo.htm [Last accessed 13 May 2010].
153. Tuberous Sclerosis Association, UK. Clinical guidelines for assessment of behaviour and learning in tuberous sclerosis complex. Available at: http://www.tuberous-sclerosis.org/publications/TSA%20Assess%20of%20Behav %20KD.pdf [Last accessed 12 May 2010].
154. Franz DN. Mental Retardation in Tuberous Sclerosis Complex. An informational fact sheet from the Tuberous Sclerosis Alliance. 2006. Available at: http://www.tsalliance.org/documents/Mental%20Retardation%20in% 20TSC.pdf [Last accessed 13 May 2010].
155. Dunn DW, Kronenberger WG. Tuberous Sclerosis Alliance. Attention deficit hyperactivity disorder and tuberous sclerosis complex. June 2006. Available at: http://www.tsalliance.org/documents/ Attention%20Deficit%20Hyperactivity%20Disorder%20and%20TSC.pdf [Last accessed 13 May 2010].
156. Wong M. Tuberous Sclerosis Complex: Mysteries, Manifestations, Mechanisms, and Management. Available at: http://neuro.wustl.edu/patientcare/ clinicalservices/tuberoussclerosisclinic/tuberoussclerosiscomplex. htm [Last accessed 13 May 2010].
157. Tuberous Sclerosis Association, UK. Behaviour in adults with tuberous sclerosis complex. 2009. Available at: http://www.tuberous-sclerosis.org/ publications/Behaviour%20in%20adults%20with%20TSC%202009.pdf [Last accessed 12 May 2010]